Oxford Biomedica Expands AAV Business into Boston
The UK-based gene and cell therapy group Oxford Biomedica, has announced the launch of their new US-based AAV manufacturing and innovation business, Oxford Biomedica Solutions LLC.
Oxford Biomedica Solutions LLC has been established following a deal between Oxford Biomedica and the genetic medicines company Homology Medicines Inc, who hold a 20% ownership. Capitalizing on Homology Medicine’s established AAV capabilities, the collaboration and expansion into the US see’s Oxford Biomedica advance their viral vector offerings.
Now in operation, Oxford Biomedica Solutions LLC offers customers a unique ‘plug and play’ process and manufacturing platform for AAV-based cell and gene therapies, protected by intellectual property. This proprietary platform provides integrated end-to-end capabilities, from viral vector design and development to clinical trial and manufacturing.
“The team is excited to be able to offer this unique platform capability to help more companies and ultimately patients. The combination of our deep expertise, innovative platform technology, and dynamic team will make for a truly differentiated capability that I am confident will contribute to addressing some of the challenges being encountered in the cell and gene therapy space today, an area Oxford Biomedica knows well,” comments Tim Kelly CEO of Oxford Biomedica Solutions.
Promising high titer, high product quality, expertise, and speed of production, the platform has already been successfully run over 600 times at representative scale, scaled to 2,000L and produced three products INDs. Its’s operational successes also include 3x500L single use bioreactors in multiple GMP suites, with over 45 successful 500L cGMP batches produced since 2019.
Customers utilizing the new platform offerings will have access to extensive AAV manufacturing experience and expertise from a team of approximately 125.
Characterized by a serum free suspension cell culture and transfection system, the platform contains a two-column chromatography purification process. Offering customers full CMC development scope for vector design, plasmid engineering, and analytical and formulation development, as well as cGMP operations for manufacturing, engineering, quality assurance, quality control and warehousing.
Expanding their already established UK presence for AAV, adenovirus and lentiviral-based cell and gene therapies into the US, will build upon Oxford Biomedica’s position as a leading global viral vector manufacturer.
“Oxford Biomedica is transforming into an innovative global viral vector leader that provides solutions to cell and gene therapy biotech and biopharma companies for their process development and manufacturing needs[…] This transaction also sees us form our first US operating subsidiary, located close to customers, talent, innovation in academia and pools of capital, which will enhance our market leadership position working across key viral vector types,” noted Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica.
Sources: Oxford Biomedica Press Release